Regester Larkin picks up 3M asthma drug PR

3M Health Care has chosen Regester Larkin to handle the pounds 300,000 fee account for its new asthma treatment.

3M Health Care has chosen Regester Larkin to handle the pounds

300,000 fee account for its new asthma treatment.



The agency, which won the account after a three-way competitive pitch,

will particularly focus on the launch of 3M’s environmentally-friendly,

CFC-free formulation of the asthma drug beclomethasone.



The drug is taken via a metered dose inhaler, a method used by 80 per

cent of adult asthma sufferers in the UK. Over the next two to three

years inhalers which use environmentally harmful CFCs are being phased

out, and are due to be banned in 2005. They will be replaced by new

inhalers which do not use CFCs. 3M’s new formulation is as effective as

previous ones, but can be taken at a lower dosage.



In 1995 3M introduced the world’s first CFC-free asthma inhaler,

Airomir, which won an award from the US Environmental Protection

Agency.



3M Health Care is part of the Minnesota-based manufacturing and science

company 3M, which has products ranging from sandpaper and masking tape

to medical and surgical supplies. 3M Health Care hit the headlines two

weeks ago when it revealed that up to 5,000 people might have been given

faulty hip implants (PR Week, 27 February 1998).



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in